

CorMedix Inc.  
Form 4  
June 01, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC., 1430 US  
HIGHWAY 206, SUITE 200

(Street)

BEDMINSTER, NJ 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
CorMedix Inc. [CRMD]

3. Date of Earliest Transaction  
(Month/Day/Year)  
05/27/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock, \$0.001 par value per share	05/27/2016		S	7,800	D	\$ 3.0419	159,599 D
					(1)		
Common Stock, \$0.001 par value per share	05/31/2016		S	42,200	D	\$ 2.8543	117,399 D
					(2)		
Common Stock,						174,741	I (3) Wade Capital

<p>\$0.001 par value per share</p>							<p>Corporation Money Purchase Plan</p>
<p>Common Stock, \$0.001 par value per share</p>				<p>10,000</p>	<p>I <sup>(3)</sup></p>		<p>Reporting Person's Wife</p>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 2.02					<u>(4)</u>	01/09/2024	Common Stock, \$0.001 par value per share	200,000
Stock Option (right to buy)	\$ 2.02					<u>(5)</u>	01/09/2024	Common Stock, \$0.001 par value per share	30,000
Swries C-3 Non-Voting Convertible Preferred Stock	\$ 1					<u>(6)</u>	<u>(6)</u>	Common Stock, \$0.001 par value per share	45,000
Warrant (right to	\$ 0.9 <sup>(7)</sup>					01/08/2015	01/08/2020	Common Stock,	22,500

purchase Common Stock)					\$0.001 par value per share	
Series C-3 Non-Voting Convertible Preferred Stock	\$ 1		<u>(7)</u>	<u>(7)</u>	Common Stock, \$0.001 par value per share	30,000
Warrant (right to purchase Common Stock)	\$ 0.9 <u>(7)</u>			01/08/2015 01/08/2020	Common Stock, \$0.001 par value per share	15,000
Stock Option (right to buy)	\$ 0.9		<u>(8)</u>	03/20/2023	Common Stock, \$0.001 par value per share	120,000
Stock Option (right to buy)	\$ 0.68		<u>(9)</u>	12/05/2022	Common Stock, \$0.001 par value per share	150,000
Stock Option (right to buy)	\$ 1.1		<u>(10)</u>	08/11/2021	Common Stock, \$0.001 par value per share	30,000
Stock Option (right to buy)	\$ 5.62		<u>(5)</u>	03/01/2025	Common Stock, \$0.001 par value per share	50,000
Stock Option (right to buy)	\$ 1.91		<u>(5)</u>	09/20/2017	Common Stock, \$0.001 par value per share	75,000

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Lefkowitz Steven W  
C/O CORMEDIX INC.  
1430 US HIGHWAY 206, SUITE 200  
BEDMINSTER, NJ 07921

X

## Signatures

Alexander M. Donalson by Power of  
Attorney

06/01/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.00 to \$3.08, inclusive.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.85 to \$2.88, inclusive.
- (3) The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
- (4) The options vested 100% on January 10, 2014.
- (5) The options vest in full on the first anniversary of the date of grant.
- On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (6) On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (7) These options vest quarterly over two years beginning June 13, 2013.
- (8) These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- (9) The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- (10)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.